It's been spectacularly successful, but with $17 billion-a-year Keytruda (pembrolizumab) now accounting for more than a third of its total sales there has been pressure on the company to diversify.
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback